EMA recommendation triggers $40M payment for blood disorder drug

Incyte and Novartis' blood disorder drug ruxolitinib was recommended for approval by the European Medicines Agency's Committee for Medicinal Products for Human Use an enlarged spleen therapy in myelofibrosis patients. The recommendation will bring Incyte a $40 million milestone payment from Novartis. The drug is called Jakavi in Europe and Jakafi in the U.S., where it was approved by the FDA in November.

View Full Article in:

Bloomberg Businessweek · Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of Massachusetts
Boston, MA
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide